Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Short Interest Update

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) saw a large drop in short interest in the month of March. As of March 31st, there was short interest totalling 5,280,000 shares, a drop of 5.9% from the March 15th total of 5,610,000 shares. Based on an average trading volume of 1,200,000 shares, the short-interest ratio is presently 4.4 days.

Alpine Immune Sciences Trading Down 0.0 %

Shares of ALPN stock traded down $0.01 on Tuesday, reaching $64.41. The company’s stock had a trading volume of 1,703,091 shares, compared to its average volume of 1,860,567. The stock’s fifty day simple moving average is $37.16 and its 200-day simple moving average is $23.49. Alpine Immune Sciences has a 1 year low of $6.71 and a 1 year high of $64.57. The company has a market capitalization of $4.22 billion, a price-to-earnings ratio of -100.66 and a beta of 1.14.

Alpine Immune Sciences (NASDAQ:ALPN) last posted its earnings results on Monday, March 18th. The biotechnology company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.47. Alpine Immune Sciences had a negative net margin of 54.66% and a negative return on equity of 15.54%. The firm had revenue of $30.85 million during the quarter, compared to analyst estimates of $6.90 million. Equities research analysts forecast that Alpine Immune Sciences will post -1.74 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Allspring Global Investments Holdings LLC boosted its stake in shares of Alpine Immune Sciences by 745.5% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,488 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 1,312 shares during the period. Royal Bank of Canada boosted its stake in shares of Alpine Immune Sciences by 99.1% during the second quarter. Royal Bank of Canada now owns 2,642 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 1,315 shares during the period. ADAR1 Capital Management LLC purchased a new stake in shares of Alpine Immune Sciences during the fourth quarter valued at $58,000. AJOVista LLC purchased a new stake in shares of Alpine Immune Sciences during the fourth quarter valued at $64,000. Finally, Public Employees Retirement System of Ohio bought a new stake in shares of Alpine Immune Sciences in the third quarter valued at about $35,000. 75.17% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ALPN. Leerink Partnrs cut shares of Alpine Immune Sciences from an “outperform” rating to a “market perform” rating in a research note on Thursday, April 11th. Morgan Stanley restated an “equal weight” rating and set a $65.00 target price (up previously from $47.00) on shares of Alpine Immune Sciences in a research note on Thursday, April 11th. Wolfe Research reiterated a “peer perform” rating on shares of Alpine Immune Sciences in a research report on Thursday, April 11th. Oppenheimer reiterated an “outperform” rating and set a $44.00 price objective (up previously from $33.00) on shares of Alpine Immune Sciences in a research report on Tuesday, March 19th. Finally, Wedbush cut shares of Alpine Immune Sciences from an “outperform” rating to a “neutral” rating in a research report on Thursday, April 11th. Eight investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $50.33.

Alpine Immune Sciences Company Profile

Alpine Immune Sciences, Inc operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.